All Drug Targets articles
-
NewsNew platform reveals shared drug targets across genetic mutations in cancer and neurodegeneration
Researchers have developed PerturbFate, a platform that simultaneously tracks gene expression, RNA dynamics and chromatin accessibility across thousands of genetic perturbations in single cells. Applied to melanoma drug resistance, the technology revealed that diverse mutations converge on shared regulatory nodes, offering a route to therapies targeting common mechanisms rather than individual genetic alterations.
-
ArticleBeyond serendipity: rational design and AI’s expansion of the undruggable target landscape
For decades, drugging the ‘undruggable’ was thought to require luck rather than logic. Today, AI is transforming serendipity into strategy by enabling rational, data-driven approaches to previously inaccessible targets.
-
NewsAI platform models protein flexibility to accelerate drug design
A new artificial intelligence platform developed at the University of Virginia addresses a critical limitation in computational drug design by modelling protein flexibility during molecular interactions. The suite of tools uses diffusion models to generate drug candidates whilst accounting for induced fit dynamics, potentially improving success rates in early-stage development.
-
NewsOntario invests $3.1M in next-generation cancer therapeutics
The Ontario Institute for Cancer Research has awarded $3.1 million to four provincial research teams developing novel cancer therapies designed to overcome drug resistance and reduce treatment-related toxicity.
-
NewsCombining antibodies with natural compounds may improve Alzheimer’s treatment
Researchers at the University of Waterloo have demonstrated that combining anti-amyloid antibodies with naturally derived small molecules, such as resveratrol and curcumin, may improve therapeutic outcomes in Alzheimer’s disease.
-
NewsInsilico announces ISM6200 AI-designed drug candidate for ovarian cancer and cortisol disorders
Insilico Medicine has nominated ISM6200, a preclinical drug candidate designed using generative AI to target NR3C1, a receptor involved in cortisol regulation.
-
NewsMassey Cancer Center funds drug discovery projects targeting Hsp27-CerS1 and ferroptosis pathways
The VCU Massey Comprehensive Cancer Center has awarded $50,000 each to two innovative drug discovery projects through its collaborative programme with Sanford Burnham Prebys Medical Discovery Institute.
-
NewsMolecular map reveals thromboxane receptor structure for new blood clotting drug development
International researchers have mapped the structure of the thromboxase A₂ receptor using cryo-electron microscopy, revealing some unexpected activation mechanisms.
-
NewsLactylation emerges as key driver of lung cancer resistance
New research from Shanghai Pulmonary Hospital outlines how lactate-driven lactylation acts as a metabolic switch controlling epigenetic regulation in lung cancer. The findings reveal self-reinforcing feedback loops that sustain drug resistance and suggest novel therapeutic strategies targeting the enzymes and pathways that maintain this process.
-
NewsNew osteoarthritis therapy targeting joint repair advances following preclinical success
A Duke Health-led consortium has achieved key preclinical milestones in developing regenerative therapies that target cartilage and bone damage in osteoarthritis, potentially offering an alternative to symptom management and joint replacement surgery.
-
WebinarWhere NAMs stand in early drug discovery: an expert discussion
Register for this webinar to discover the role of NAMs in drug discovery.
-
NewsLipid nanoparticles deliver dual therapy for lung cancer
Oregon State University researchers have developed engineered lipid nanoparticles that deliver follistatin mRNA directly to lung tumours, simultaneously targeting cancer growth and muscle-wasting cachexia in preclinical studies.
-
ArticleImproving selectivity in antibody–drug conjugates
Promatix Biosciences is developing a new generation of bispecific antibody–drug conjugates using proprietary membrane proteomics data to identify highly selective target pairings. CEO Dr Michael Hunter explains how the company’s TXPro database enables discovery of previously unexplored tumour biology to improve therapeutic index and reduce on-target/off-tumour toxicities in solid tumours.
-
WebinarManufacturing the Future: From N=1 Personalized CRISPR Therapy to Scalable Precision Genomic Medicine
How biotech leaders are turning one-off CRISPR breakthroughs into scalable, regulatory-ready therapies.
-
NewsFGF21 hormone targets hindbrain pathways to reverse obesity
New research reveals that FGF21, a hormone under investigation for obesity and metabolic dysfunction-associated steatohepatitis (MASH), works by signalling to the hindbrain rather than the hypothalamus. The discovery of this distinct neural circuit—which increases metabolic rate rather than simply suppressing appetite—could enable development of more precise therapies with fewer adverse effects than current FGF21 analogues.
-
NewsSmall molecule SK-129 targets protein aggregation in Parkinson’s disease
International researchers have identified a small molecule capable of crossing the blood-brain barrier to prevent pathological protein aggregation in Parkinson’s disease, Lewy body dementia and multiple system atrophy.
-
ArticleFrom fragments to maps: scaling drug–target interaction data
Most drug–target data were never designed to be compared at scale. Pharmome mapping takes a different approach, building a shared dataset intended to support more predictable discovery.
-
NewsHuman antimicrobial peptide dermcidin shows antiviral activity against influenza
Researchers at Fisabio Foundation have discovered that dermcidin, an antimicrobial peptide naturally present in human sweat, exhibits antiviral activity against influenza by binding to viral haemagglutinin and preventing cell fusion, opening new possibilities for innate immunity-based therapeutics.
-
NewsMirrored molecules target disordered proteins in Alzheimer’s disease
Researchers at Kobe University have developed a novel approach to Alzheimer’s disease treatment by engineering right-handed amino acid chains that bind to amyloid-beta proteins. The method, inspired by materials science principles of chirality, demonstrated effective inhibition of toxic protein aggregation in mouse brain cell cultures, maintaining cell viability where amyloid-beta alone reduced it by 50 percent.
-
ReportCRISPR & Genomics: Turning Data into Confident Drug Discovery Decisions
Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.